about
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomasHematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.Development of Novel Immunotherapies for Multiple MyelomaRecent advances in understanding multiple myelomaMaintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injuryOlder patients with myeloma derive similar benefit from autologous transplantation.Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography.Data on alteration of hormone and growth factor receptor profiles over progressive passages of breast cancer cell lines representing different clinical subtypesSuppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation.Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialOutcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow upPerforming and processing FNA of anterior fat pad for amyloid.Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphomaSystemic and microvascular oxidative stress induced by light chain amyloidosis.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationAllogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndromeTrends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisDisparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myelomaEffect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteinsSafety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphomaSecond autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosisEngraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management ApproachReduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.Cure of multiple myeloma -- more hype, less reality.Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphomaAutologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchDAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation.New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell TransplantationMultiple myeloma: charging toward a bright future.Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain ProteinsMonocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation.
P50
Q26784108-069A5C10-A010-45A0-A363-A4DC0449FB3CQ27691802-24384C85-15A1-436B-B3C9-CD48FC0EC4B9Q28066890-9A56475C-9C07-446B-A3DF-E1134F2F9B92Q28070331-312902EF-342F-477B-BA9D-CBB5BF941868Q30275382-CA50F239-D0DD-49CD-9562-DA7B46336CD2Q30275582-1326754F-1A25-483F-94E4-D687FACE18CDQ30301228-F1305B04-7FF2-4DAF-ABCB-F4413B587079Q30355633-88FE59BB-EEFB-41C0-92CD-49E260134AD1Q30370038-30520962-AC96-42E8-B849-518A014F3D34Q30483215-04A13EB3-B306-4A3B-B123-F9109C9F151CQ31120851-9EA8F68D-4536-4A9A-955F-B8F4855D6050Q33263439-7E1C0E02-E208-47DE-AF62-4499C5CEE611Q33401218-D3B8FE74-DFC3-48D2-B3AB-9154DBFCC42FQ33414827-941E3C23-6860-441A-8845-3626F85FCB24Q33419056-A10F9956-128B-417E-9633-D1FBA949B83AQ33439299-099B25EF-1C5A-4ED2-9A0B-497E67EB87BBQ33749311-1D686DAC-55C4-400C-A8BE-BE2D8EB33E50Q34034292-FCEDEC27-18A8-4C40-B9C7-CD8B64ACBD66Q34283343-1AB8FDE1-CBA4-4415-A5C7-BB1C2C793C97Q34325329-6C208A21-85B0-4758-971A-25ED7D03712BQ34459010-F27CD47A-93E2-4025-B293-5A6AABCA938AQ35172500-06C5CADA-0FB6-4DF3-ACD3-6ACBDCF364ADQ35180533-F22B7FDF-3AAD-4D82-8CEA-55BF2DDE919FQ35219011-4A6FF86D-4245-4899-857E-23B02D54F478Q35601377-8DFC4F0A-D0F4-4C89-888A-E76244887B8EQ35812033-33CBE92F-343D-4442-8BF4-6384266D4317Q35964878-7D760407-EEF3-436C-9606-85E4796C7FBAQ36035591-F23139A7-3B89-47B7-91A4-597DDC9C2223Q36036322-64426BF4-9328-4729-9A6E-37F4C3A236D0Q36199790-9C7BF812-24FF-4D01-B4F2-F4D48A20F110Q36264701-5C027709-957B-4EE6-9646-E385106E45A7Q36264884-AE7D273E-B9F4-43D4-AA2F-7683AC0F65F3Q36301128-AF5BCFF2-494B-48CE-894D-FACE708B8A13Q36436907-29990568-6FDD-4D04-9F57-5DAFA820E8A2Q36557201-7B895D7D-C612-41EA-8954-178201457CB7Q36568965-3E55D90D-AE95-4E6E-98E9-017919778230Q36712121-087A3768-6F3F-4295-8064-50B3DA65B779Q36940402-A342A404-ACC8-40C7-B6B2-CAC5D9738238Q37076162-6D004895-EA49-4B90-B156-0B50B24947A0Q37115027-EA552656-1CAA-4BCB-B822-E13FFA3FA2B0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Parameswaran Hari
@ast
Parameswaran Hari
@en
Parameswaran Hari
@es
Parameswaran Hari
@nl
Parameswaran Hari
@sl
type
label
Parameswaran Hari
@ast
Parameswaran Hari
@en
Parameswaran Hari
@es
Parameswaran Hari
@nl
Parameswaran Hari
@sl
prefLabel
Parameswaran Hari
@ast
Parameswaran Hari
@en
Parameswaran Hari
@es
Parameswaran Hari
@nl
Parameswaran Hari
@sl
P106
P1153
12760213200
P31
P496
0000-0002-8800-297X